RxDoctor Payments Data

Randal Lepow, DPM

Podiatrist · Houston, TXNPI 1245210830

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (29.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Kerecis Limited at 49.2% of the total. Reporting peaked in 2022 at $11,445 and has fallen 92.8% since, to $827 in 2025. Among podiatrist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,696in general payments, 2019–2025

Across 260 payments — averaging $125.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$16K
  • Medinc Of Texas$5K
  • Biotissue Holdings Inc.$3K
  • Stryker$2K
  • Smith+Nephew$2K
  • Medline Industries LP$602
  • plus $5K from 36 others
$1,600in research payments, 2019–2025

Across 1 payment — averaging $1600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Skye Orthobiologics LLC$2K

What the payments were for

  • Consulting fees$3,75011%
  • Speaking & faculty fees$5,81318%
  • Travel & lodging$8,41826%
  • Food & beverage$9,70230%
  • Education$5,01315%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,696 in reported general payments places this provider in the 90th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$381,813
Medicare patients
176
Services billed
1,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.59$32,266
Ciclopirox42$1,441
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip34$964
Ammonium Lactate29$860
Cephalexin32$266
Clindamycin Hcl23$251
Methylprednisolone34$166
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$162
Levofloxacin17$105
Terbinafine Hcl13$93
Tramadol Hcl17$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,846$32,26659 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 470 podiatrist providers in Texas.

Other podiatrist in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →